Mutation of tet2 gene and malignant blood disease.
- Author:
Xi-Feng QIAN
1
;
Yun-Feng SHEN
;
Su-Jiang ZHANG
;
Jian-Yong LI
Author Information
1. Department of Hematology, Wuxi People Hospital, Nanjing Medical University, Wuxi 214000, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
DNA-Binding Proteins;
genetics;
Hematologic Diseases;
genetics;
Humans;
Mutation;
Myelodysplastic Syndromes;
genetics;
Myeloproliferative Disorders;
genetics;
Proto-Oncogene Proteins;
genetics
- From:
Journal of Experimental Hematology
2010;18(4):1096-1100
- CountryChina
- Language:Chinese
-
Abstract:
Tet2 (the 2nd member of tet oncogene family) is a newly discovered antioncogene on the chromosome 4q24 of the patient with malignant myeloma, which has a potential for functional deletion. Recent studies demonstrated that tet2 mutation was found in polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis, systematic mastocytosis (SM), and myelodysplastic syndrome (MDS). However, a great number of perspective researches are still needed for exploring the role of tet2 in the pathogenesis of malignant blood diseases. In this review, the relation of tet2 mutation with myeloproliferative neoplasm, systemic mastocytosis, myelodysplastic syndrome, acute myeloid leukemia and other malignant blood diseases are summarized.
